Lilly announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin Value Program which caps patients’ out-of-pocket costs at $35 per month or less. Of note, President Joe Biden has already issued a statement stating Lilly’s move is “a big deal, and it’s time for other manufacturers to follow” (view article). Below, FENIX provides highlights and insights into Lilly’s rationale for the price reductions as well as an RAI and basal insulin pricing analysis.